Shanghai Shyndec Pharmaceutical Co., Ltd.SSE: 600420

Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

· Issued by Shanghai Shyndec Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

The drug, known as the injectable form of a certain compound, is approved for production and is intended for treating peripheral artery diseases and inner ear circulation disorders.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Shanghai Shyndec Pharmaceutical Co., Ltd. on 6ix

Earlier from Shanghai Shyndec Pharmaceutical

Later from Shanghai Shyndec Pharmaceutical

All Shanghai Shyndec Pharmaceutical news releases